DR. STEVEN M. LARSON, O.D. PSY.D.
Optometry at 42 St, New York, NY

2013003, Feb 14, 2013

Jul 2, 2010

13/381209

Michelle Bradbury - New York NY, US
Ulrich Wiesner - Ithaca NY, US
Oula Penate Medina - New York NY, US
Andrew Burns - Niskayuna NY, US
Jason Lewis - New York NY, US
Steven Larson - New York NY, US

CORNELL UNIVERSITY - Ithaca NY
SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH - New York NY

A61K 49/00, A61K 49/06, A61K 49/04, A61K 9/14, A61K 39/395, A61K 31/7088, A61K 48/00, A61K 31/56, A61K 31/713, A61K 31/7105, G01N 21/64, A61P 35/00, A61P 31/04, A61P 31/00, A61P 39/06, A61P 37/06, A61P 7/02, A61P 9/08, A61P 29/00, A61K 51/12, B82Y 5/00, B82Y 15/00

424 137, 424 96, 424 93, 424 94, 424490, 4241781, 514 44 A, 514 44 R, 514169, 435 723, 977773, 977906, 977927, 977928, 977930

The present invention provides a fluorescent silica-based nanoparticle that allows for precise detection, characterization, monitoring and treatment of a disease such as cancer The nanoparticle has a fluorescent compound positioned within the nanoparticle, and has greater brightness and fluorescent quantum yield than the free fluorescent compound To facilitate efficient urinary excretion of the nanoparticle, it may be coated with an organic polymer, such as polyethylene glycol) (PEG) The small size of the nanoparticle, the silica base and the organic polymer coating minimizes the toxicity of the nanoparticle when administered in vivo The nanoparticle may further be conjugated to a ligand capable of binding to a cellular component associated with the specific cell type, such as a tumor marker A therapeutic agent may be attached to the nanoparticle Radionuclides/radiometals or paramagnetic ions may be conjugated to the nanoparticle to permit the nanoparticle to be detectable by various imaging techniques.

2011010, May 5, 2011

Nov 4, 2010

12/939807

Gabriela Chiosis - New York NY, US
Huazhong He - New York NY, US
Joungnam Kim - Forest Hills NY, US
Steven M. Larson - New York NY, US
Peter Smith-Jones - New York NY, US

SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH - New York NY

A61K 31/52, C07D 473/34, A61P 35/00, A61K 51/00, A61P 43/00, C12N 5/02

424 165, 544276, 544277, 51426324, 51426337, 5142634, 435375

Hsp90 inhibitors having are provided having the formula:with a 2′,4′,5′-substitution pattern on the right-side aryl moiety. X1 represents two substituents, which may be the same or different, disposed in the 4′ and 5′ positions on the aryl group, wherein X1 is selected from halogen, alkyl, alkoxy, halogenated alkoxy, hydroxyalkyl, pyrollyl, optionally substituted aryloxy, alkylamino, dialkylamino, carbamyl, amido, alkylamido dialkylamido, acylamino, alkylsulfonylamido, trihalomethoxy, trihalocarbon, thioalkyl, SOalkyl, COO-alkyl, KH, OH, CN, SOX, NO, NO, C═SRNSOX, C═OR, where Xis F, NH2, alkyl or H, and Ris alkyl, NH, NH-alkyl or O-alkyl, Cto Calkyl or alkoxy; or wherein Xhas the formula -0-(CH)-0-, wherein n is an integer from O to 2, preferably 1 or 2, and one of the oxygens is bonded at the 5′-position and the other at the 4′-position of the aryl ring. The compounds are useful in cancer therapy and as radioimaging ligands.

2011030, Dec 8, 2011

Jun 15, 2009

12/999120

Steven Larson - New York NY, US

SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH - New York NY

A61K 51/04, C12N 5/09

424 189, 435375

Compositions containing three and four-carbon acids labeled with F at the 2-position and to their use for emission tomography are disclosed.